![Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial - Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -](https://www.thelancet.com/cms/attachment/72c725a0-6956-4523-b345-3d6fbb9958d3/gr3.jpg)
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -
![Second booster vaccination against COVID-19 | Advisory report | The Health Council of the Netherlands Second booster vaccination against COVID-19 | Advisory report | The Health Council of the Netherlands](https://www.healthcouncil.nl/binaries/large/content/gallery/gezondheidsraad/content-afbeeldingen/hero-bij-adviezen/vaccinaties/verpleegkundige-vaccineert-man-unsplash_hero.jpg)
Second booster vaccination against COVID-19 | Advisory report | The Health Council of the Netherlands
![Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine](https://www.thelancet.com/cms/asset/ed9fb7c0-6950-4f6d-a114-f54b85a105fe/gr1.jpg)
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom - eBioMedicine
![Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial - Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -](https://www.thelancet.com/cms/asset/3b19b20c-8a5a-43c9-80d5-abbcb3039e22/gr1.jpg)
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -
Boosters improve diminished protection against Omicron infection after basic COVID-19 vaccination or previous infection | RIVM
![Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster | BioSpace Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster | BioSpace](https://mms.businesswire.com/media/20220511006129/en/1453980/4/Patient_receiving_first_dose_of_Akston_Biosciences_AKS-452_booster_vaccine_in_Phase_II_trial_-_12_May_2022.jpg)
Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster | BioSpace
![Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial - Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -](https://www.thelancet.com/cms/attachment/3d186965-5d25-4d1a-a4a3-e4c329ca4400/gr4.jpg)
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial -
![Want to mix and match booster shots? Here's why public health officials aren't letting you — yet | Salon.com Want to mix and match booster shots? Here's why public health officials aren't letting you — yet | Salon.com](https://mediaproxy.salon.com/width/1200/https://media.salon.com/2021/10/covid-19-coronavirus-vaccine-shot-bottle-syringe-1018211.jpg)